Axel Hoos, Scorpion Therapeutics CEO

Scor­pi­on scores $65M as it lines up a part­ner to take EGFR pro­grams glob­al

Ax­el Hoos is fir­ing up an­oth­er cylin­der in pur­suit of Scor­pi­on Ther­a­peu­tics’ vi­sion for pre­ci­sion on­col­o­gy 2.0, and it in­volves bring­ing a Eu­ro­pean play­er to his cor­ner.

Scor­pi­on will earn $65 mil­lion in up­front and near-term mile­stones for team­ing up with French phar­ma Pierre Fab­re to co-de­vel­op and com­mer­cial­ize two of its pre­clin­i­cal pro­grams that are slat­ed for IND fil­ings over the next year. While the part­ners each take the lead on one of the pro­grams, the com­mer­cial rights will be split by ge­og­ra­phy, with Scor­pi­on keep­ing rights in the US, Cana­da and Japan while Pierre Fab­re takes charge every­where else.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.